China leads the way, and extracellular follicle technology has ushered in a new era of cancer

capital boost, extracellular vesicle technology to the Blue Sea Recently, ILIAS Biologics announced that it had completed a $20.6 million round of financing in South Korea.
since its inception in November 2015, ILIAS has raised $40.2 million.
According to incomplete statistics, in 2019, the global financing of extracellular vesicles has exceeded 2000, the amount of financing in 2019 exceeded 1 billion yuan, by the end of 2019, the two indicators are a total of more than 13,000 financing projects, the total amount of financing of more than 8 billion yuan.
including scientists such as Harvard University and City University of Hong Kong, as well as many companies and investment institutions have been involved in the research and commercialization of extracellular vesicles, becoming the most active investment field and new hot spot.
the beginning of this year, the global health and economy have been greatly affected by the new crown outbreak, but several collaborations and transactions in the field of extracellular follicles continue to focus on the field of extracellular follicles.
According to publicly disclosed information, there will be about $4 billion in domestic mergers and acquisitions in 2019, representing a total of 20 transactions, an increase of about 300 percent and 25 percent, respectively, compared with 2018, with the anti-tumor sector and immunotherapy also hot tracks in global mergers and acquisitions.
including Tencent, Jinman investment lead investment, Lanfeng Capital, Enron Ventures and other institutions have laid out the field of extracellular vesicles in advance.
At the same time, after the opening of the A-share section, the fifth set of listing standards will also greatly promote the financing of innovative medical enterprises, providing a new listing path for unprofitable biopharmaceutical enterprises, more and more enterprises and capital targeting the above-mentioned areas.
currently, most of the clinical transformation of extracellular follicles worldwide progresses to preclinical or clinical stage 1.
But China's source of innovative "drug-carrying vesicle treatment tumor technology" has completed the clinical transformation in the Chinese market, one after another in Hubei, Hunan, Hebei, Shandong, Anhui, Shenzhen, Tianjin 7 provinces and cities approved for use, has become the current global extracellular vesicle research and clinical transformation of the most advanced new tumor treatment technology.